Literature DB >> 33302762

A Response to the Recommendations for Using Dexamethasone for the Treatment of COVID-19: The Dark Side of Dexamethasone.

Mohamed A Salem1.   

Abstract

Entities:  

Year:  2020        PMID： 33302762     DOI： 10.1177/0897190020979608

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN： 0897-1900


× No keyword cloud information.
  5 in total

Review 1.  Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients?

Authors:  Ganna Stepanova
Journal:  Biol Futur       Date:  2021-06-08

2.  Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis.

Authors:  Kentaro Shimizu; Haruhiko Hirata; Daijiro Kabata; Natsuko Tokuhira; Moe Koide; Akiko Ueda; Jotaro Tachino; Ayumi Shintani; Akinori Uchiyama; Yuji Fujino; Hiroshi Ogura
Journal:  J Infect Chemother       Date:  2021-12-31       Impact factor: 2.211

3.  Harm of early dexamethasone for COVID-19 and bias in randomized trials.

Authors:  Isaac Núñez; Yanink Caro-Vega; Adrian Soto-Mota
Journal:  Eur J Intern Med       Date:  2022-09-19       Impact factor: 7.749

Review 4.  COVID-19 immunopathology: From acute diseases to chronic sequelae.

Authors:  Mohd Arish; Wei Qian; Harish Narasimhan; Jie Sun
Journal:  J Med Virol       Date:  2022-09-03       Impact factor: 20.693

Review 5.  Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?

Authors:  Nithin K K; Prakash Patil; Satheesh Kumar Bhandary; Vikram Haridas; Suchetha Kumari N; Sarathkumar E; Praveenkumar Shetty
Journal:  F1000Res       Date:  2021-04-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.